Amphastar Pharmaceuticals Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Amphastar Pharmaceuticals Inc (AMPH) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Amphastar Pharmaceuticals Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 730M vs 106,112M combined for tracked competitors (0.7% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+0.8% annualized vs trailing 12 months), vs holding steady (-0.5%) for its tracked peer group.
- Growth: Amphastar Pharmaceuticals Inc generated 5.4% revenue growth year over year in Q2 2026, vs 2.9% for its tracked competitors combined.
- Profitability: Its 16.5% net margin compares with -3.0% for the peer group.
- Scale: Amphastar Pharmaceuticals Inc ranks #140 of 544 companies by market capitalization in the Major Pharmaceutical Preparations industry, holding 0.0% of industry market cap.
- Peer revenue share: Amphastar Pharmaceuticals Inc accounted for 0.7% of combined revenue among its tracked peer group, up from 0.7% a year earlier.
- Peer differentiation: Revenue per employee of $0.37M compares with $0.89M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AMPH Sales vs. its Competitors, Q2 2026
Amphastar Pharmaceuticals Inc reported revenue growth of 5.44 % year on year in Q2 2026, above its competitors' combined revenue growth of 2.92 %.
With a net margin of 16.50 %, Amphastar Pharmaceuticals Inc achieved higher profitability than its competitors (-2.97 %).
Amphastar Pharmaceuticals Inc generated 0.69 % of the combined sales of its peer group, up from 0.68 % a year earlier.
Amphastar Pharmaceuticals Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Amphastar Pharmaceuticals Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Amphastar Pharmaceuticals Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Amphastar Pharmaceuticals Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 5.4% for Amphastar Pharmaceuticals Inc. Amphastar Pharmaceuticals Inc's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.00 percentage points.
Amphastar Pharmaceuticals Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | Yes | Yes | No | No |
| Competitors combined (24) | ||||
| High-Confidence Competitors (5) | ||||
| Similar-Size Competitors (9) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AMPH Stock Performance relative to its Competitors
AMPH Stock Performance relative to High-Confidence Competitors
AMPH Stock Performance relative to Similar-Size Competitors
AMPH Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Cidara Therapeutics Inc | 282.9% | Outperformed |
| 2 | Verona Pharma Plc | 282.9% | Outperformed |
| 3 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 4 | Cumberland Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Amphastar Pharmaceuticals Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Amphastar Pharmaceuticals Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Amphastar Pharmaceuticals Inc | 1,211.32 | 730.02 |
| Novartis Ag | 287,150.40 | 56,674.00 |
| Pfizer Inc | 163,675.28 | 63,696.00 |
| Sanofi | 100,940.42 | 52,321.04 |
| Teva Pharmaceutical Industries Limited | 45,295.20 | 14,105.00 |
| Viatris Inc | 21,253.49 | 14,737.30 |
| SUBTOTAL | 665,009.11 | 239,078.39 |
Sign in to see all competitors of Amphastar Pharmaceuticals Inc .
Sources: Amphastar Pharmaceuticals Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Amphastar Pharmaceuticals Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Amphastar Pharmaceuticals Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Halozyme Therapeutics Inc | Named by the company | 85% |
| Opiant Pharmaceuticals Inc | Named by the company | 85% |
| Xeris Biopharma Holdings Inc | Named by the company | 85% |
| Teva Pharmaceutical Industries Ltd | Named by the company | 85% |
| Viatris Inc | Named by the company | 85% |
| Amring Pharmaceuticals | Named by the company | 85% |
| Sandoz Inc | Named by the company | 85% |
| American Regent Inc | Named by the company | 85% |
| Sun Pharmaceuticals | Named by the company | 85% |
| Sagent Pharmaceuticals | Named by the company | 85% |
| Apotex Corp | Named by the company | 85% |
| Cipla USA Inc | Named by the company | 85% |
| Zydus Pharmaceuticals USA Inc | Named by the company | 85% |
| Hikma Pharmaceuticals | Named by the company | 85% |
| Medefil Inc | Named by the company | 85% |
| Meithael Pharmaceuticals | Named by the company | 85% |
| Amneal Biosciences | Named by the company | 85% |
| Meitheal Pharmaceuticals | Named by the company | 85% |
| AuroMedics Pharma LLC | Named by the company | 85% |
| Nexus Pharmaceuticals | Named by the company | 85% |
| Par Pharmaceuticals | Named by the company | 85% |
| Akorn Inc | Named by the company | 85% |
| Korn Ferry | Named by the company | 85% |
| Pfizer Inc | Named by the company | 85% |
| Amneal Pharmaceuticals Inc | Named by the company | 85% |
| Sanofi | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Amphastar Pharmaceuticals Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Amphastar Pharmaceuticals Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amphastar Pharmaceuticals Inc | Finished Pharmaceutical Products Segment 100.00 % |
| Pfizer Inc | U.S. Commercial Division 52.92 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
| Amneal Pharmaceuticals Inc | Affordable Medicines 58.61 % |
| Korn Ferry | Consulting 23.96 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
Amphastar Pharmaceuticals Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 1,211 | 369,443 | 39,751 |
| Novartis Ag | 287,150 | 752,973 | 185,566 |
| Pfizer Inc | 163,675 | 849,280 | 58,267 |
| Sanofi | 100,940 | 22,927,713 | 3,853,252 |
| Teva Pharmaceutical Industries Limited | 45,295 | 415,464 | 20,884 |
| Viatris Inc | 21,253 | 491,243 | -13,690 |
| PEERS TOTAL | 663,798 | 886,508 | 82,134 |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
Amphastar Pharmaceuticals Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Amphastar Pharmaceuticals Inc | US 92.91 % |
| Pfizer Inc | United States 58.91 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Perrigo Company Plc | United States 57.24 % |
| Ars Pharmaceuticals Inc | US 76.95 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Amphastar Pharmaceuticals Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Amphastar Pharmaceuticals Inc's industry classification, broader than the peer set above. Market cap in millions of $.Amphastar Pharmaceuticals Inc ranks #140 of 498 companies by market capitalization in its industry, holding 0.02 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 140 | Amphastar Pharmaceuticals Inc | 1,193 | 0.02 % |
Market cap and industry share for the rest of Amphastar Pharmaceuticals Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Amphastar Pharmaceuticals Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 135 | Damora Therapeutics Inc | 1,246 | 357.98 % |
| 136 | Xtl Biopharmaceuticals Ltd | 1,237 | -52.31 % |
| 137 | Opko Health Inc | 1,227 | 13.64 % |
| 138 | Harrow Inc | 1,206 | -30.03 % |
| 139 | First Tracks Biotherapeutics Inc | 1,234 | 12.3% |
| 140 | Amphastar Pharmaceuticals Inc | 1,193 | 2.31 % |
| 141 | Nanobiotix S a | 1,234 | 12.3% |
| 142 | Kailera Therapeutics Inc | 1,234 | 12.3% |
| 143 | Chemomab Therapeutics Ltd | 1,234 | 12.3% |
| 144 | Alto Neuroscience Inc | 1,234 | 12.3% |
| 145 | Lb Pharmaceuticals Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Amphastar Pharmaceuticals Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Amphastar Pharmaceuticals Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 47.68 % | 64.89 % (avg) | -17.2 pp |
| Operating Margin | 15.66 % | industry median | +69.3 pp |
| EBITDA Margin | 23.98 % | -7.21 % (avg) | +31.2 pp |
| Capital Intensity (Capex / Revenue) | 4.34 % | 4.92 % (avg) | -0.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Amphastar Pharmaceuticals Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 11.6x | 25.1x | -13.5x |
| EV / EBITDA | 6.7x | 17.3x | -10.5x |
| P/B | 1.1x | 4.5x | -3.4x |
| Return on Equity | 10.11 % | industry aggregate | -7.14 % |
| Return on Invested Capital | 5.08 % | -2.95 % (avg) | 8.03 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Amphastar Pharmaceuticals Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 23.04 % | 9.40 % | 8.53 % | 25.13 % | 13.98 % | 29.14 % | 13.88 % | -1.90 % |
| Operating Margin | -2.93 % | -0.01 % | 3.13 % | 15.96 % | 21.54 % | 30.57 % | 25.61 % | 19.50 % |
| Return on Invested Capital | -1.17 % | 0.00 % | 1.10 % | 6.88 % | 9.54 % | 11.69 % | 9.09 % | 6.33 % |
| P/E | - | 19.2x | - | 17.9x | 16.8x | 21.9x | 13.6x | 13.1x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Amphastar Pharmaceuticals Inc's Strategic Group Map
Every company in Amphastar Pharmaceuticals Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Amphastar Pharmaceuticals Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Amphastar Pharmaceuticals Inc's BCG Growth-Share Matrix
Relative market share (vs Amphastar Pharmaceuticals Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Amphastar Pharmaceuticals Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 8.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Amphastar Pharmaceuticals Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Moderate, in line with the industry | Capital intensity (capex / revenue) of 4.34 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Amphastar Pharmaceuticals Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Amphastar Pharmaceuticals Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Amphastar Pharmaceuticals Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Amphastar Pharmaceuticals Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Amphastar Pharmaceuticals Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 69.3 points above the industry median.
Weaknesses
- Return on equity 7.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
Opportunities
- Trades at a lower P/E than the industry average (11.6x vs 25.1x) despite a higher return on invested capital -- a possible re-rating opportunity.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Amphastar Pharmaceuticals Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 1.00 | 3.21 | 0.79 |
| Novartis Ag | 0.42 | 1.12 | 0.02 |
| Pfizer Inc | 0.04 | 1.24 | 0.71 |
| Sanofi | 0.27 | 1.09 | 0.20 |
| Teva Pharmaceutical Industries Limited | 0.24 | 1.00 | 2.15 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Amphastar Pharmaceuticals Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | Q2 2026 | +5.4 % | -2.2 % |
| Novartis Ag | Q4 2025 | +9.6 % | +17.0 % |
| Pfizer Inc | Q2 2026 | +2.6 % | - |
| Sanofi | Q4 2025 | +5.5 % | +39.7 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -0.8 % | - |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| PEERS TOTAL | +2.0 % | +39.5 % |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Amphastar Pharmaceuticals Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | Q2 2026 | +2.9 % | -33.0 % |
| Novartis Ag | Q4 2025 | +18.3 % | +13.3 % |
| Pfizer Inc | Q2 2026 | +8.3 % | -13.8 % |
| Sanofi | Q4 2025 | -1.2 % | - |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -4.1 % | - |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
Amphastar Pharmaceuticals Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 4.70% | 5.33% | 10.11% |
| Novartis Ag | 12.59% | 12.62% | 30.00% |
| Pfizer Inc | 2.12% | 2.53% | 4.91% |
| Sanofi | 6.19% | 8.42% | 10.95% |
| Teva Pharmaceutical Industries Limited | 1.77% | 2.66% | 9.11% |
| Viatris Inc | - | - | - |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Amphastar Pharmaceuticals Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Amphastar Pharmaceuticals Inc | 16.21 | 1.66 |
| Novartis Ag | 20.53 | 5.07 |
| Pfizer Inc | 37.66 | 2.57 |
| Sanofi | 11.43 | 1.93 |
| Teva Pharmaceutical Industries Limited | 63.88 | 3.21 |
| Viatris Inc | - | 1.44 |
| PEERS AVERAGE | 30.01 | 2.78 |
Sign in to see all peers for Amphastar Pharmaceuticals Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.